Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann-Kathrin Bittner

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Fertility and Sterility|April 9, 2011
Hormone-induced delayed ovulation affects early embryonic developmentAnn-Kathrin Bittner, Bernhard Horsthemke, Elke Winterhager, et al.
Frontiers in Oncology|October 5, 2020
Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast CancerSabine Kasimir-Bauer, Corinna Keup, Oliver Hoffmann, et al.
Journal of Cellular and Molecular Medicine|June 20, 2020
Molecular characterization of circulating tumour cells identifies predictive markers for outcome in primary, triple-negative breast cancer patientsAnn-Kathrin Bittner, Corinna Keup, Oliver Hoffmann, et al.
Breast Cancer Research : BCR|February 13, 2016
Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapySabine Kasimir-Bauer, Ann-Kathrin Bittner, Lisa König, et al.
Scientific Reports|May 24, 2016
Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?Sabine Kasimir-Bauer, Katharina Reiter, Bahriye Aktas, et al.
Molecular and Clinical Oncology|April 29, 2016
B3-lesions of the breast and cancer risk - an analysis of mammography screening patientsOliver Hoffmann, Gesina Athina Stamatis, Ann-Kathrin Bittner, et al.
Journal of Cancer Research and Clinical Oncology|April 2, 2022
Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapseOliver Hoffmann, Sebastian Wormland, Ann-Kathrin Bittner, et al.
BMC Cancer|February 6, 2019
Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancerLisa König, Fabian D Mairinger, Oliver Hoffmann, et al.
Breast Care (Basel, Switzerland)|September 26, 2022
The Role of C-Reactive Protein as a Prognostic Biomarker in Patients with Early Breast Cancer Treated with Neoadjuvant ChemotherapyAlexandra Edimiris-Herrmann, Cornelia Kolberg-Liedtke, Ann-Kathrin Bittner, et al.
Archives of Gynecology and Obstetrics|February 27, 2024
High serum levels of leucine-rich α-2 glycoprotein 1 (LRG-1) are associated with poor survival in patients with early breast cancerAndy Göbel, Tilman D Rachner, Oliver Hoffmann, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Fertility and Sterility|April 9, 2011
Hormone-induced delayed ovulation affects early embryonic developmentAnn-Kathrin Bittner, Bernhard Horsthemke, Elke Winterhager, et al.
Frontiers in Oncology|October 5, 2020
Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast CancerSabine Kasimir-Bauer, Corinna Keup, Oliver Hoffmann, et al.
Journal of Cellular and Molecular Medicine|June 20, 2020
Molecular characterization of circulating tumour cells identifies predictive markers for outcome in primary, triple-negative breast cancer patientsAnn-Kathrin Bittner, Corinna Keup, Oliver Hoffmann, et al.
Breast Cancer Research : BCR|February 13, 2016
Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapySabine Kasimir-Bauer, Ann-Kathrin Bittner, Lisa König, et al.
Scientific Reports|May 24, 2016
Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?Sabine Kasimir-Bauer, Katharina Reiter, Bahriye Aktas, et al.
Molecular and Clinical Oncology|April 29, 2016
B3-lesions of the breast and cancer risk - an analysis of mammography screening patientsOliver Hoffmann, Gesina Athina Stamatis, Ann-Kathrin Bittner, et al.
Journal of Cancer Research and Clinical Oncology|April 2, 2022
Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapseOliver Hoffmann, Sebastian Wormland, Ann-Kathrin Bittner, et al.
BMC Cancer|February 6, 2019
Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancerLisa König, Fabian D Mairinger, Oliver Hoffmann, et al.
Breast Care (Basel, Switzerland)|September 26, 2022
The Role of C-Reactive Protein as a Prognostic Biomarker in Patients with Early Breast Cancer Treated with Neoadjuvant ChemotherapyAlexandra Edimiris-Herrmann, Cornelia Kolberg-Liedtke, Ann-Kathrin Bittner, et al.
Archives of Gynecology and Obstetrics|February 27, 2024
High serum levels of leucine-rich α-2 glycoprotein 1 (LRG-1) are associated with poor survival in patients with early breast cancerAndy Göbel, Tilman D Rachner, Oliver Hoffmann, et al.
Pageof 4